Provectus receives fourth pharmaceutical patent for anti-cancer agents

By Lisa Kerner

Erie, Pa., Jan. 31 - Provectus Pharmaceuticals, Inc. said it has received its 14th U.S. patent (U.S. Patent 6,991,776) and the fourth U.S. patent for its pharmaceutical products.

The latest patent covers use of Provectus' anticancer pharmaceutical agent PV-10 for radiosensitization, according to a company news release.

In preclinical studies, the small-molecule, tumor-specific agent PV-10 was shown to enhance the effectiveness of conventional radiation therapy. Provectus said it is testing PV-10 in a chemoablative formulation, known as Provecta, in clinical trials for treatment of metastatic melanoma and breast cancer.

The latest patent augments coverage provided by the company's earlier patents for cancer treatment and diagnostic imaging using CT, MRI and ultrasound.

Provectus designs, develops and markets pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. The company is based in Knoxville, Tenn.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.